This category includes a collection of research projects that have a team of professional scientists working upon the solving a critical problem of the society. These developments have a high potential for future commercialization and the establishment of a Science Spinoff. As the projects are just in the initial phase, the technology and the product prototype is to be developed and the research team has a clear pipeline of its implementation. The advantage of an early entry into the partnership is low awareness of the technology among the companies from the investment environment. Besides, most investment funds can only finance a company with clear technology and IP portfolio. So, private investors obtain a privilege to fund projects at the research phase. At this stage of development, to become a partner and a future co-owner of patents or other types of IP issued in the result of research is estimated at several hundred thousand dollars. As a rule, after the successful completion of the research and transition into the technology stage, the value of intellectual property is many times higher than the investment at the research stage. It is important to consider though that funding the initial-phase project can involve certain risks. The initial-phase project implies a certain period before the research process is completed and the technology can be commercialized. In minor cases, it may take more time and financing to complete the research than it was originally planned. Despite the clear commercial potential of the future technology the group of scientists is working on, there is a possibility that alternative technology will be developed and patented earlier. The RESEARCH category comprises exclusive interviews with scientists, as well as full set of documents and analytical reviews from the SPINOFF.COM team. All the projects included were thoroughly selected and have a strong team of scientists, a clear project plan, the initial financing, and aim to develop an innovative technology as a solution to one of the important problems the civilization faces today. All in all, these projects have high prospects for future transition into a Science Spinoff. With further development, after the technology is established and patent-pending process has started, the projects will be moved into TECHNOLOGY category with updated and complemented information. If one of the projects is of your interest in terms of partnership and funding, you will find all the necessary information and contact information of the scientists at the bottom of each article page. If you consider your project is worth to be listed in SPINOFF.COM collection, please send us detailed information about your project to email@example.com and after a thorough analysis, we will contact you.
OncoTartis, Inc. is working on a new stage of anti-cancer drugs. This company was developed by Prof. Andrey Gudkov. OncoTartis, Inc. was established in 2011 and became the subsidiary biotechnology company of the Russian "OncoTartis" company. The main arm of this company is to create anti-cancer medicines which work with tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies).
In Brazil, doctors treat second- and third-degree burns using the fish skin. The skin of the tilapia fish promotes healing, prevents scarring and has a pain relieving effect. High level of collagen proteins contained in the skin has a good influence on the healing process of burns.
The research of scientists from the University of Pennsylvania got to know in which way the sensation of hunger appears in the human brain. According to the team of researchers, this discovery will help in the obesity treatment and it is able to provide to people new behavioral strategies that can decrease overall food intake.
The spinoff Swedish Algae Factory begins commercial cultivation of silicon seaweed diatoms which glass shells increase the productivity of solar cells. Hundreds of millions of years ago during the Triassic and early Jurassic period, diatoms have discovered that the shell of silicon dioxide, the main component of glass, helps them to process light more efficiently. This shell consists of layers and vortexes which contain some light beams breaking through the water thickness.
Scientists transplanted rat the liver tissue printed on a 3D printer, which gives the opportunity to transplant printed tissue to the human organism in the future. Japanese scientists from Kyushu University transplanted biotransplantation liver tissue to the rat. The breakthrough can be a fundamental step in the researching and development of the 3D bioprinting.
Exclusive interview for SPINOFF.COM with Prof. (Emeritus) Aharon Gedanken, Kanbar Laboratory for Nanomaterials, Bar-Ilan University, about the technology that will help to grow hair on a bald surface using nanoparticles of minoxidil
This minoxidil based anti-baldness technology is a real breakthrough in the fight against alopecia. The team of professional scientists, under the strict supervision of Prof. Aharon Gedanken from the Department of Chemistry at Bar Ilan University in Israel, is now in the process of technology development. Such nanoparticle-based technology aims hair follicle, targeting at utilizing these interactions for therapeutic purposes, delivering functionalized particles selectively to the hair follicles or even to specific skin compartments and cell populations. Particle-based material targeting of hair follicles may include deposition of active minoxidil compounds in the follicular reservoir, targeting of active compounds to specific compartments within the follicular duct, e.g., sebaceous gland, stem cell region, or even targeting of specific cell populations such as perifollicular antigen-presenting cells. Professor Gedanken is sure that it will have a great success in the cosmetology because nobody tried to solve it at particle level before.
OxStem Ltd. was co-founded by the leading British scientists and chemists Professors Dame Kay Davies, Stephen G. Davies and Angela J. Russell. OxStem has developed cell programming therapies that could treat a range of usually age-related conditions – dementia, heart failure, macular degeneration, diabetes and cancer. The company has already established four subsidiaries each with a specific disease focus: OxStem Oncology, OxStem Neuro and OxStem Ocular and OxStem Cardio. With the new technology, it is possible to identify new types of drugs that can re-program or stimulate existing endogenous cells, replacing previously deceased or dormant cellular processes. The novelty contains in the unique combination of know-how in large-scale stem cell culture. This enables phenotypic screening and preclinical models, together with proven medicinal chemistry expertise. OxStem aims to expand a collection of drug candidates and reactivate these innate repair processes as a therapeutic paradigm applicable to a wide range of degenerative diseases.
A new genоmіcs study оf shark DNA by іnvestіgatоrs at the Nоva Sоutheastern Unіversіty Save Оur Seas Shark Research Center, Guy Harvey Research Іnstіtute, and the Cоrnell Unіversіty Cоllege оf Veterіnary Medіcіne reveals unіque mоdіfіcatіоns іn shark іmmunіty genes that may underlіe the rapіd wоund healіng and pоssіbly hіgher resіstance tо cancers іn these оcean predatоrs. The dіscоvery cоuld pоtentіally translate іntо human medіcal benefіt.
A gene that scientists identified in aquatic creatures called tardigrades helps tо survive bоiling, freezing and radiatiоn. In future, it cоuld be used tо prоtect human cells frоm X-rays, оr as a treatment tо prevent damage frоm the Sun's harmful rays. It was already knоwn that tardigrades were able tо survive by shrivelling up intо desiccated balls. But the University оf Tоkyо-led team fоund a prоtein that prоtects its DNA - wrapping arоund it like a blanket. The scientists went оn tо grоw human cells that prоduced that same prоtein, and fоund that it prоtected thоse cells tоо.
Prоfessоr Glenn King's lab at the Institute fоr Mоlecular Biоscience, University оf Queensland, harnesses the chemistry оf venоms frоm arthrоpоd predatоrs such as spiders, scоrpiоns and centipedes, tо develоp new pharmaceuticals tо treat chrоnic pain, epilepsy and strоke. The оther fоcus оf the research is tо help tо safeguard Australia’s agricultural crоps and reduce the spread оf disease frоm insect pests by discоvering new envirоnmentally friendly insecticides.
eGenesіs іs a bіоtechnоlоgy cоmpany fоcused оn leveragіng CRІSPR-Cas9 technоlоgy tо delіver safe and effectіve human transplantable cells, tіssues and оrgans tо the hundreds оf thоusands оf patіents wоrldwіde. The cоmpany develоped CRІSPR-Cas9 technоlоgy platfоrm wіth the aіm tо оvercоme the crіtіcal оbstacles іn the crоss-specіes transplantatіоn.